
## Stereoselective Total Synthesis of Rugulactone<sup>1</sup>)

by Biswanath Das\*, Yallamalla Srinivas, Chithaluri Sudhakar, and Parigi Raghavendar Reddy

Organic Chemistry Division-I, Indian Institute of Chemical Technology, Hyderabad-500007, India (phone: +91-40-7193434; fax: +91-40-7160512; e-mail: biswanathdas@yahoo.com)

The stereoselective synthesis of the naturally occurring dihydropyranone rugulactone has been accomplished starting from 3-phenylpropan-1-ol employing *Maruoka* allylation and ring-closing metathesis as the key steps.

**Introduction.** – Natural products containing a dihydropyranone moiety are known to possess a wide range of biological properties, including antibacterial, antifungal, antifeedant, and cytotoxic activities [1]. Rugulactone (1), a member of this group, was isolated from *Cryptocarya rugulosa* [2]. The compound inhibits constitutive NF- $\kappa$ B activity in human lymphoma cell lines. Due to the interesting structural pattern and impressive bioactivity, the synthesis of this compound has been an important target for organic chemists [3–6]. In continuation of our work on the total synthesis of natural products [7–10], here we report an efficient approach for the stereoselective synthesis of compound 1.



**Results and Discussion.** – The retrosynthetic analysis (*Scheme 1*) indicates that rugulactone (1) can be synthesized from the keto ester 2. The latter, in turn, can be obtained from the alkenol 3 generated *via* an alkyne 4 from 3-phenylpropan-1-ol (5).


In the present synthesis (*Scheme 2*), the commercially available 3-phenylpropan-1ol (**5**) was oxidized under *Swern* conditions, and the resulting aldehyde was treated with tetrahydro-2*H*-pyran-2-yl (THP) protected homopropargyl alcohol in the presence of BuLi to afford the secondary alcohol **4**.

The alkyne moiety in **4** was reduced with  $\text{LiAlH}_4$  in THF under reflux to furnish the alkenol **6**. The OH group was protected as  $(t-\text{Bu})\text{Ph}_2\text{Si}$  (TBDPS) ether by reacting with TBDPSCl in the presence of 1*H*-imidazole to afford **7** in high yield. The THP group of **7** was removed by treatment with PPTS in MeOH to provide the primary alcohol **3**.


<sup>1)</sup> Part 42 in the series 'Synthetic Studies on Natural Products'.

<sup>© 2011</sup> Verlag Helvetica Chimica Acta AG, Zürich






This alcohol was oxidized with 2-iodoxybenzoic acid (IBX) in dry DMSO to form the corresponding aldehyde, which, *via Maruoka* asymmetric allylation with the titanium complex (*S*,*S*)-**I** and (allyl)(tributyl)stannane, yielded the homoallylic alcohol **8** (97% ee) [11]. Compound **8** was esterified with acryloyl chloride in the presence of Et<sub>3</sub>N to give the acryloyl ester **9** required for ring-closing metathesis [12][13]. The TBDPS group of **9** was removed with a catalytic amount of Bu<sub>4</sub>NF (TBAF) to afford the alcohol **1**, which was oxidized with *Dess–Martin* periodinane (DMP) to afford the desired keto ester **2**. The ring-closing metathesis (RCM) of **2** was successfully achieved by using *Grubbs*' 2nd-generation catalyst (5 mol-%) to produce rugulactone (**1**). This RCM was described earlier in the first total synthesis of **1** [3] and also used by us in the synthesis of two similar natural products [7][8]. The structures of all the products involved in the present synthesis were established by their spectroscopic data (IR, <sup>1</sup>H-and <sup>13</sup>C-NMR, and MS). The physical and spectroscopic properties of the prepared **1** were identical to those reported earlier [2–6].



In conclusion, a new stereoselective total synthesis of the naturally occurring bioactive compound rugulactone (1) has been achieved starting from 3-phenylpropan-1-ol (5) by applying *Maruoka* asymmetric allylation and ring-closing metathesis as the key steps. This synthetic method can conveniently be utilized for the preparation of various analogs of rugulactone useful for biological evaluations.





a) 1. Oxalyl chloride, DMSO, Et<sub>3</sub>N, -78°; 82%; 2. BuLi, dry THF, THP-protected homopropargyl alcohol (=but-3-yn-1-ol), -78°, 3 h; 87%. b) LiAlH<sub>4</sub>, dry THF, 0° to reflux, 3 h; 78%. c) (t-Bu)Ph<sub>2</sub>SiCl (TBDPSCl), 1*H*-imidazole, CH<sub>2</sub>Cl<sub>2</sub>, 0° to r.t., 2 h; 90%. d) Pyridinium *p*-toluenesulfonate (PPTS), MeOH, r.t., 12 h; 79%. e) 1. 2-Iodoxybenzoic acid (IBX), DMSO, dry CH<sub>2</sub>Cl<sub>2</sub>, 0° to r.t., 2 h; 76%, 2. (*S*,*S*)-I, allyl(tributyl)tin, -15 to 0°, 16 h; 74%. *f*) Acryloyl chloride (= prop-2-enoyl chloride), Et<sub>3</sub>N, 4-(dimethylamino)pyridine (DMAP), CH<sub>2</sub>Cl<sub>2</sub>, 0° to r.t., 4 h; 78%. *g*) Bu<sub>4</sub>NF (TBAF), dry THF, 0° to r.t., 1 h; 80%. *h*) *Dess–Martin* periodinane (DMP), dry CH<sub>2</sub>Cl<sub>2</sub>, 0° to r.t., 4 h; 77%. *i*) *Grubbs*' 2nd-generation catalyst (5 mol-%), CH<sub>2</sub>Cl<sub>2</sub>, reflux, 6 h; 75%.

The authors thank UGC and CSIR, New Delhi, for financial assistance.

## **Experimental Part**

General. Column chromatography (CC): silica gel (SiO<sub>2</sub>; 100–200 mesh; *BDH*). TLC: silica gel  $GF_{254}$  precoated plates (*Merck*). Optical rotations: *Jasco Dip 360* digital polarimeter. IR Spectra: *Perkin-Elmer RX1* FT-IR spectrophotometer. NMR Spectra: *Varian Gemini* 200 MHz, *Bruker* 300-MHz (<sup>1</sup>H) and 50-MHz (<sup>13</sup>C) spectrometers. ESI-MS: *VG-Autospec micromass.* 

*1-Phenyl-7-(tetrahydro-2*H-*pyran-2-yloxy)hept-4-yn-3-ol* (**4**). To a stirred soln. of oxalyl chloride (0.73 ml, 12.13 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (30 ml), DMSO (0.55 ml, 18.2 mmol) was added at  $-78^{\circ}$ , and the mixture was stirred at the same temp. for 0.5 h. A soln. of *3-phenylpropan-1-ol* (**6**; 1 g, 6.06 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 ml) was added at  $-78^{\circ}$ , and the mixture was stirred for 1.5 h at the same temp. Et<sub>3</sub>N (4.21 ml,

Scheme 2

30.33 mmol) was added at 0°, and the mixture was stirred for an additional 30 min. The mixture was diluted with H<sub>2</sub>O (30 ml) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 50 ml). The combined org. layers were washed with brine (20 ml), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to give the corresponding aldehyde (0.80 g, 82%) as a colorless liquid. Because of extensive oxidation of the aldehyde to the corresponding acid, we have used it immediately for the next step.

Under N<sub>2</sub>, a soln. of BuLi in hexane (6.0 ml, 9.62 mmol, 1.6M soln.) was added to a soln. of the THP ether of homopropargyl alcohol (0.99 g, 7.2 mmol) in THF (45 ml) at  $-78^{\circ}$ , and the mixture was stirred for 30 min. Finally, a soln. of 3-phenylpropanal (0.80 g, 6.0 mmol) in dry THF (40 ml) was added. After stirring the mixture for 3 h at  $-78^{\circ}$ , the reaction was quenched by adding sat. aq. NH<sub>4</sub>Cl soln. (30 ml). The mixture was extracted with AcOEt (2 × 50 ml) and dried (anh. Na<sub>2</sub>SO<sub>4</sub>). Evaporation of the solvents gave the crude alcohol, which was purified by CC to afford the pure alcohol **4** (1.74 g, 87%). Light yellowish liquid. IR (neat): 3419, 2941, 2227, 1451, 1126, 1066, 1031. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.26 – 7.10 (m, 5 H); 4.63 (br. t, J = 3.0, 1 H); 4.28 (br. t, J = 6.2, 1 H); 3.88–3.73 (m, 2 H); 3.56–3.44 (m, 2 H); 2.76 (t, J = 7.7, 2 H); 2.52–2.43 (m, 2 H); 2.00–1.45 (m, 8 H). <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 141.4; 128.5; 125.9; 98.7; 82.6; 81.9; 65.7; 62.2; 61.8; 39.4; 31.4; 30.5; 25.3; 20.1; 19.3. ESI-MS: 308 ([M + NH<sub>4</sub>]<sup>+</sup>).

(4E)-1-Phenyl-7-(tetrahydro-2H-pyran-2-yloxy)hept-4-en-1-ol (6). To the suspension of LiAlH<sub>4</sub> (0.2 g, 5.22 mmol) in dry THF (16 ml) under N<sub>2</sub> at 0° was added **4** (1.5 g, 5.22 mmol) in dry THF (35 ml), and the mixture was stirred at r.t. for 3 h. The mixture was cooled to 0°, diluted with Et<sub>2</sub>O, and the reaction was quenched with sat. Na<sub>2</sub>SO<sub>4</sub> soln. (10 ml). When the effervescence subsided, the mixture was filtered through a pad of *Celite*, and washed with CH<sub>2</sub>Cl<sub>2</sub> (30 ml) and hot AcOEt (30 ml). The filtrate was washed with brine (2 × 40 ml), dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated under vacuum, and the residue was purified by CC to furnish **6** (1.17 g, 78%). Colorless liquid. IR (neat): 3421, 2932, 2861, 1602, 1451, 1124, 1069, 1030. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.26–7.08 (*m*, 5 H); 5.71–5.50 (*m*, 2 H); 4.55 (br. *t*, *J* = 2.8, 1 H); 4.02 (*q*, *J* = 7.0, 1 H); 3.85–3.67 (*m*, 2 H); 3.50–3.34 (*m*, 2 H); 2.76–2.58 (*m*, 2 H); 2.31 (*q*, *J* = 7.0, 2 H); 1.91–1.44 (*m*, 9 H). <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 141.9; 134.7; 128.4; 128.3; 128.2; 125.6; 98.7; 72.1; 66.8; 62.3; 38.6; 32.6; 31.7; 30.6; 25.3; 19.5. ESI-MS: 291 ([*M* + H]<sup>+</sup>).

(tert-Butyl)(diphenyl)[[(4E)-1-phenyl-7-(tetrahydro-2H-pyran-2-yloxy)hept-4-en-3-yl]oxy]silane(7). To a stirred soln. of **6** (1.17 g, 4.05 mmol) and 1*H*-imidazole (0.63 g, 10.14 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (30 ml) was added TBDPSCl (1.33 g, 4.86 mmol) portionwise at 0°. The mixture was stirred at the same temp. for 2 h, and then the reaction was quenched with H<sub>2</sub>O. The CH<sub>2</sub>Cl<sub>2</sub> layer was separated, and the aq. layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> (2 × 20 ml). The combined org. layers were washed with H<sub>2</sub>O (20 ml) and brine (20 ml), and dried (anh. Na<sub>2</sub>SO<sub>4</sub>). Solvent was removed *in vacuo*, and the residue was purified by CC to afford **7** (1.92 g, 90% yield). Colorless liquid. IR (neat): 2934, 2858, 1739, 1595, 1461, 1428, 1358, 1111, 1071, 1032. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.66 – 7.59 (*m*, 4 H); 7.41 – 7.27 (*m*, 6 H); 7.18 – 6.94 (*m*, 5 H); 5.49 (*dd*, *J* = 15.0, 7.0, 1 H); 5.33 – 5.31 (*m*, 1 H); 4.53 – 4.49 (*m*, 1 H); 4.14 – 4.10 (*m*, 1 H); 3.80 – 3.74 (*m*, 1 H); 3.63 – 3.59 (*m*, 1 H); 3.46 – 3.42 (*m*, 1 H); 3.25 – 3.19 (*m*, 1 H); 2.58 – 2.49 (*m*, 2 H); 2.22 – 2.12 (*m*, 2 H); 1.86 – 1.41 (*m*, 8 H); 1.06 (*s*, 9 H). <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 142.4; 135.9; 135.8; 134.2; 129.4; 129.3; 128.3; 128.2; 127.7; 127.6; 127.4; 127.2; 125.5; 98.7; 73.9; 66.8; 62.1; 39.6; 32.5; 31.0; 30.6; 27.0; 25.4; 19.5; 19.3. ESI-MS: 551 ([*M* + Na]<sup>+</sup>).

(3E)-5-{[(tert-Butyl)(diphenyl)silyl]oxy]-7-phenylhept-3-en-1-ol (**3**). To a stirred soln. of **8** (1.92 g, 3.63 mmol) in MeOH (20 ml) was added a cat. amount of PPTS (0.2 g, 0.90 mmol). The mixture was stirred at r.t. for *ca.* 12 h. MeOH was removed under reduced pressure. The crude residue was purified by CC to afford **3** (1.43 g, 79%). Viscous liquid. IR (neat): 3365, 2933, 2958, 1666, 1596, 1463, 1427, 1363, 1108. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.63 – 7.55 (*m*, 4 H); 7.38 – 7.24 (*m*, 6 H); 7.19 – 6.96 (*m*, 5 H); 5.45 (*dd*, J = 15.0, 7.0, 1 H); 5.13 – 5.11 (*m*, 1 H); 4.16 – 4.08 (*m*, 1 H); 3.37 (*t*, J = 6.3, 2 H); 2.51 (*t*, J = 7.3, 2 H); 2.06 (*q*, J = 6.3, 2 H); 1.87 – 1.64 (*m*, 2 H); 0.99 (*s*, 9 H). <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 142.2; 135.9; 135.8; 135.6; 134.3; 134.2; 129.5; 129.4; 128.3; 128.2; 127.5; 127.3; 127.2; 125.6; 73.9; 61.7; 39.7; 35.4; 31.1; 26.9; 19.3. ESI-MS: 467 ([M + Na]<sup>+</sup>).

(4S,6E)-8-{[(tert-Butyl)(diphenyl)silyl]oxy]-10-phenyldeca-1,6-dien-4-ol (8). To an ice-cooled soln. of 2-iodoxybenzoic acid (1.06 g, 1.28 mmol) in DMSO (1.35 ml, 28.9 mmol) was added a soln. of 3 (1.43 g, 3.219 mmol) in anh. CH<sub>2</sub>Cl<sub>2</sub> (10 ml). The mixture was stirred at r.t. for 2 h, then filtered through a *Celite* pad, and washed with Et<sub>2</sub>O (100 ml). The combined org. filtrates were washed with H<sub>2</sub>O (15 ml)

and brine (15 ml), dried (anh.  $Na_2SO_4$ ), and concentrated *in vacuo*. The crude product was purified by CC to afford aldehyde as a colorless liquid (1.08 g, 76%).

To a stirred soln. of TiCl<sub>4</sub> (0.01 ml, 0.12 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 ml) was added dried Ti(O<sup>i</sup>Pr)<sub>4</sub> (0.102 ml, 0.22 mmol) at 0° under N<sub>2</sub>. The soln. was allowed to warm to r.t. After 1 h, Ag<sub>2</sub>O (0.05 g, 0.24 mmol) was added at r.t., and the mixture was stirred for 5 h under exclusion of direct light. The mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 ml) and treated with (*S*)-binaphthol (0.14 g, 0.49 mmol) at r.t. for 2 h to furnish chiral bis[Ti(IV)oxide] (*S*,*S*)-**I**. The *in situ* generated (*S*,*S*)-**I** catalyst was cooled to  $-15^{\circ}$  and treated sequentially with the above prepared aldehyde (1.08 g 2.43 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 ml) and allyl(tributyl)tin (1.06 g, 3.16 mmol) at  $-15^{\circ}$ . The whole mixture was allowed to warm to 0° and stirred for 16 h. The reaction was quenched with sat. NaHCO<sub>3</sub> (10 ml), and the mixture was extracted with Et<sub>2</sub>O (100 ml). The org. extracts were dried (Na<sub>2</sub>SO<sub>4</sub>). Evaporation of solvents and purification of the residue by CC afforded **8** (0.94 g, 74%). Colorless liquid. IR (neat): 3386, 3028, 2921, 2852, 1674, 1634, 1406, 1268, 1191, 1048. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.76–7.63 (*m*, 5 H); 7.53–7.32 (*m*, 7 H); 7.24–7.08 (*m*, 3 H); 5.83–5.66 (*m*, 3 H); 5.18–5.06 (*m*, 2 H); 4.32–4.28 (*m*, 1 H); 3.83–3.79 (*m*, 1 H); 2.58–2.20 (*m*, 4 H); 1.99–1.51 (*m*, 2 H); 1.12 (*s*, 9 H). <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 142.0; 134.1; 132.3; 130.2; 130.0; 129.8; 129.5; 129.3; 128.4; 128.2; 126.0; 115.8; 75.5; 74.1; 42.5; 41.2; 40.5; 31.7; 25.8; 19.5. ESI-MS: 485 ([*M* + H]<sup>+</sup>).

(4S,6E)-8-{[(tert-Butyl)(diphenyl)sily]oxy}-10-phenyldeca-1,6-dien-4-yl Prop-2-enoate (9). To a stirred soln. of **8** (0.94 g, 1.94 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 ml) was added acryloyl chloride (0.26 g, 2.92 mmol) and Et<sub>3</sub>N (0.39 g, 3.89 mmol) at 0°. The mixture was allowed to warm to r.t., and stirred for 4 h. The mixture was diluted with H<sub>2</sub>O (10 ml) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 × 10 ml). The combined org. layer was dried (Na<sub>2</sub>SO<sub>4</sub>), and the solvent was removed under vacuum to obtain the crude residue, which was purified by CC to afford pure **9** (1.51 g, 78%). Colorless oil. IR (neat): 3028, 2921, 2852, 1724, 1675, 1633, 1407, 1269, 1190, 1049. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.75 – 7.60 (*m*, 5 H); 7.50 – 7.32 (*m*, 7 H); 7.24 – 7.08 (*m*, 3 H); 6.41 – 6.39 (*m*, 1 H); 6.22 – 6.00 (*m*, 2 H); 5.92 – 5.85 (*m*, 4 H); 5.17 – 5.06 (*m*, 3 H); 4.50 – 4.48 (*m*, 1 H); 4.02 – 4.0 (*m*, 1 H); 2.66 – 2.36 (*m*, 6 H); 1.96 – 1.66 (*m*, 2 H); 1.12 (*s*, 9 H). ESI-MS: 539 ([*M* + H]<sup>+</sup>).

(4S,6E)-8-Hydroxy-10-phenyldeca-1,6-dien-4-yl Prop-2-enoate (10). To a soln. of **9** (0.80 g, 1.48 mmol) in dry THF (10 ml) was added TBAF (1.48 ml, 1.48 mmol, 1M soln. in THF) dropwise at 0°, and the mixture was stirred for 1 h. H<sub>2</sub>O (20 ml) was added, and the mixture was extracted with AcOEt (50 ml). The org. extracts were washed with brine (30 ml) and dried (Na<sub>2</sub>SO<sub>4</sub>). Evaporation of the solvent afforded **10** (0.35 g, 80%). Colorless liquid. IR (neat): 3429, 3028, 2921, 2852, 1723, 1674, 1634, 1406, 1268, 1191, 1048. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.37 – 7.15 (*m*, 5 H); 6.76 – 6.72 (*m*, 1 H); 6.39 (*dd*, *J* = 17.3, 1.5, 1 H); 6.18 – 6.02 (*m*, 2 H); 5.87 – 5.67 (*m*, 2 H); 5.16 – 5.04 (*m*, 2 H); 1.46 – 4.44 (*m*, 1 H); 4.11 – 4.07 (*m*, 1 H); 2.71 – 2.57 (*m*, 2 H); 2.48 – 2.39 (*m*, 2 H); 2.30 – 2.23 (*m*, 2 H); 1.88 – 1.69 (*m*, 2 H). <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 166.4; 140.9; 131.8; 129.6; 126.9; 124.4; 116.3; 77.1; 71.9; 39.9; 37.8; 32.2; 29.0. ESI-MS: 301 ( $[M + H]^+$ ).

(4S,6E)-8-Oxo-10-phenyldeca-1,6-dien-4-yl Prop-2-enoate (2). To a stirred soln. of **10** (0.35 g, 0.66 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (15 ml), *Dess–Martin* periodinane (0.40 g, 0.972 mmol) was added at 0° and the mixture was stirred for 4 h at r.t. The reaction was quenched with sat. NaHCO<sub>3</sub> soln./hypo soln. = Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> soln. (1:1; 15 ml) and stirred for 30 min and then extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 20 ml). The combined org. layers were washed with H<sub>2</sub>O (10 ml), dried (anh. Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude residue was purified by CC to afford pure (0.26 g, 77%). Viscous liquid. IR (neat): 3429, 3028, 2921, 2852, 1723, 1674, 1634, 1406, 1268, 1191, 1048. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.32–7.26 (*m*, 3 H); 7.21–7.18 (*m*, 2 H); 6.77–6.71 (*m*, 1 H); 6.39 (*dd*, *J* = 17.2, 1.4, 1 H); 6.17–6.04 (*m*, 2 H); 5.83 (*dd*, *J* = 10.2, 1.2, 1 H); 5.76–5.72 (*m*, 1 H); 5.14–5.06 (*m*, 2 H); 4.56–4.50 (*m*, 1 H); 2.97–2.82 (*m*, 4 H); 2.56–2.47 (*m*, 2 H); 2.37 (*t*, *J* = 6.6, 2 H). <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 199.1; 165.5; 141.6; 132.8; 132.7; 131.1; 128.5; 128.3; 126.1; 118.5; 71.7; 41.7; 38.1; 36.5; 30.0; 29.7. ESI-MS: 321 ([*M* + Na]<sup>+</sup>).

(6R)-6-[(2E)-4-Oxo-6-phenylhex-2-en-1-yl]-5,6-dihydro-2H-pyran-2-one (1) [3]. To a stirred soln. of benzylidine[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]dichloro(tricyclohexylphosphine)-ruthenium (*Grubbs*' 2nd-generation catalyst; 8 mg, 5 mol-%) in CH<sub>2</sub>Cl<sub>2</sub> (40 ml) at 55° was added to **2** (0.26 g, 0.07 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 ml). The resulting mixture was stirred for 6 h, after which time all of the starting material had been consumed (TLC). The solvent was removed under reduced

pressure to yield a crude product, which was purified by CC to give pure **1** (0.182 g, 75%). Yellow oil. IR (neat): 3444, 2924, 2854, 1717, 1631, 1450, 1382, 1244, 1039. <sup>1</sup>H-NMR (200 MHz, CDCl<sub>3</sub>): 7.33–7.23 (*m*, 3 H); 7.23–7.17 (*m*, 2 H); 6.92–6.73 (*m*, 2 H); 6.20 (*d*, *J* = 15.8, 1 H); 6.05 (*d*, *J* = 9.0, 1 H); 4.57–4.53 (*m*, 1 H); 2.98–2.88 (*m*, 4 H); 2.71–2.60 (*m*, 2 H); 2.40–2.31 (*m*, 2 H). <sup>13</sup>C-NMR (50 MHz, CDCl<sub>3</sub>): 199.0; 163.7; 144.6; 141.0; 140.0; 133.5; 128.5; 128.4; 126.1; 121.5; 76.1; 41.7; 37.2; 29.9; 28.9. ESI-MS: 288 ([*M* + NH<sub>4</sub>]<sup>+</sup>).

## REFERENCES

- S. D. Rychnovsky, *Chem. Rev.* 1995, 95, 2021; S. E. Drewes, B. M. Sehlapelo, M. M. Horn, R. Scott-Shaw, O. Sandor, *Phytochemistry* 1995, 38, 1427; R. Pereda-Miranda, M. Fragoso-Serremo, C. M. Cerda-García-Rojas, *Tetrahedron* 2001, 57, 47; M. Carda, S. Rodríguez, F. González, E. Castillo, A. Villanueva, J. A. Marco, *Eur. J. Org. Chem.* 2002, 2649; H. Kikuchi, K. Sasaki, J. Sekiya, Y. Maeda, A. Amagai, Y. Kubohara, Y. Oshima, *Bioorg. Med. Chem.* 2004, *12*, 3203; A. de Fátima, L. K. Kohn, M. A. Antonio, J. E. de Carvalho, R. A. Pillia, *Bioorg. Med. Chem.* 2005, *13*, 2927.
- [2] T. L. Meragelman, D. A. Scudiero, R. E. Davis, L. M. Staudt, T. G. McCloud, J. H. Cardellina II, R. H. Shoemaker, J. Nat. Prod. 2009, 72, 336.
- [3] D. K. Mohapatra, P. P. Das, D. S. Reddy, J. S. Yadav, Tetrahedron Lett. 2009, 50, 5941.
- [4] D. K. Reddy, V. Shekhar, T. S. Reddy, S. P. Reddy, Y. Venkateswarlu, *Tetrahedron: Asymmetry* 2009, 20, 2315.
- [5] D. K. Reddy, V. Shekhar, P. Prabhakar, B. C. Babu, B. Siddhardha, U. S. N. Murthy, Y. Venkateswarlu, *Eur. J. Med. Chem.* 2010, 45, 4657.
- [6] G. Reddipalli, M. Venkataiah, N. W. Fadnavis, *Tetrahedron: Asymmetry* 2010, 21, 320.
- [7] B. Das, K. Suneel, G. Satyalakshmi, D. N. Kumar, Tetrahedron: Asymmetry 2009, 20, 1536.
- [8] B. Das, K. Laxminarayana, M. Krishnaiah, D. N. Kumar, Bioorg. Med. Chem. Lett. 2009, 19, 6396.
- [9] B. Das, K. Laxminarayana, M. Krishnaiah, D. N. Kumar, Helv. Chim. Acta 2009, 92, 1840.
- [10] B. Das, M. Krishnaiah, C. Sudhakar, Bioorg. Med. Chem. Lett. 2010, 20, 2303.
- [11] H. Hanawa, T. Hashimoto, K. Maruoka, J. Am. Chem. Soc. 2003, 125, 1708.
- [12] A. K. Chatterjee, J. P. Morgan, M. Scholl, R. H. Grubbs, J. Am. Chem. Soc. 2000, 122, 3783.
- [13] R. H. Grubbs, Tetrahedron 2004, 60, 7117.

Received October 25, 2010